Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis.
Repurposing drugs for disease modification in multiple sclerosis
Genzyme provides update on U.S. LEMTRADA™ filing
Teriflunomide for multiple sclerosis.
Berlex continues legal challenge to FDA over MS drug.
Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis.
The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets.
LKB1/STRAD promotes axon initiation during neuronal polarization.
Molecular characterization of a peripheral receptor for cannabinoids.
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial.
Emerging oral agents for multiple sclerosis.
Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up.
Extension CombiRx data show no benefit of combined MS drugs
Reversible pulmonary artery hypertension in association with interferon-beta therapy for multiple sclerosis.
Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis.
IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.
A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
Rituximab (marketed as Rituxan), Information
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
Current and future immunotherapy targets in autoimmune neurology.
Insight into the mechanism of laquinimod action.
Increased incidence of central nervous system hemorrhages in patients with secondary acute promyelocytic leukemia after treatment of multiple sclerosis with mitoxantrone?
Treatment of neurological injury with thymosin β4.

Pages